ClinicalTrials.gg
CompletedNCT00753649Updated Nov 27, 2019Results posted

Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants

A Phase 4 interventional study of Infanrix™ hexa in Hepatitis B, Tetanus and Poliomyelitis, sponsored by GlaxoSmithKline. Completed at 3 sites in Canada. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-27.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
224
Allocation
Non-randomized
Ages
6 Weeks to 12 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Hepatitis B.

Enrollment
12th of 16
224 · median 417
Started
2008
with 2 others
Phase 4
6 of 16
none open now
Registered
7th of 16
by date
Lead sponsor
14 of 16
GlaxoSmithKline

Among the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B, this one is the 12th largest by enrollment, is one of 3 that started in 2008, is one of 6 in phase 4, and was the 7th registered.

Hepatitis B

1,048 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

None of the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B is open now. The open studies under Hepatitis B, anywhere →

About diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B as a file.
02

Study summary

This study will evaluate GSK Biologicals' DTPa-HBV-IPV/Hib vaccine given as a three-dose primary vaccination course at 2, 4 and 6 months of age, in terms of safety and immunogenicity in different population of infants residing in Canada.

Read the detailed description

This protocol posting has been updated following Protocol amendment 1 (19-MAY-2010).

03

Conditions studied

  • Hepatitis B
  • Tetanus
  • Poliomyelitis
  • Diphtheria
  • Haemophilus Influenzae Type b
  • Acellular Pertussis

Keywords

  • Infant
  • First nation
  • Aboriginal
  • Canada
04

Who can participate

Ages eligible
6 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that their parent/guardian can and will comply with the requirements of the protocol should be enrolled in the study.
  • A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.
  • Born after a gestation period of 36 to 42 weeks inclusive.
  • Healthy subjects as established by medical history before entering into the study.
  • Written obtained from the parent or guardian of the subject.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of or other immune-modifying drugs from birth until first primary vaccination dose..
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Major congenital defects or serious chronic illness.
  • Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis, and/or Hib vaccination or disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • The following condition is temporary or self limiting and a subject may be vaccinated once the condition has resolved and no other exclusion criteria are met:
  • Current febrile illness or axillary temperature of ≥ 37.5 ºC or other moderate to severe illness within 24 hours of study vaccine administration.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    Aboriginal infants group

    Biological: Infanrix™ hexa

  • Active comparator
    Other Non-Aboriginal infants

    Biological: Infanrix™ hexa

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (Anti-PRP)

    A seroprotected subject was a subject whose anti-PRP antibody concentration was greater or equal to (≥) 0.15 microgram per milliliter (µg/mL).

    Time frame: One month after (POST) Dose 3.

Secondary outcomes

  1. Number of Subjects With Anti-PRP Antibody Concentrations ≥1µg/mL

    For this assay, 1 μg/mL was considered as the seropositivity cut-off.

    Time frame: One month after (POST) Dose 3.

  2. Anti-PRP Antibody Concentrations

    Anti-PRP antibody concentrations were presented as Geometric mean Concentrations (GMC), expressed as micrograms per milliliter (μg/mL).

    Time frame: One month after (POST) Dose 3.

  3. Number of Seroprotected Subjects Against Hepatitis B (Anti-HBs)

    A seroprotected subject was a subject with anti-HBs antibody concentrations ≥ 10 milli-International Units ler milliliter (mIU/mL). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following partial or complete retesting/reanalysis. Some of the available blood samples initially tested with ELISA were re-tested using the new assay, CLIA.

    Time frame: One month after (POST) Dose 3.

  4. Number of Subjects With Anti-HBs Antibody Concentrations ≥100 mIU/mL

    The testing was done using the Enzyme-Linked Immunosorbent assay (ELISA) assay.

    Time frame: One month after (POST) Dose 3.

  5. Anti-HBs Antibody Concentrations

    Anti-HBs antibody concentrations were assessed by Enzyme-Linked Immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs).

    Time frame: One month after (POST) Dose 3.

  6. Number of Subjects With Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

    Time frame: During the 31 day (Days 0-30) post vaccination

  7. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: During the entire study period up to Last subject last visit on 03/12/2013

07

Results

Posted Nov 30, 2016
Limitations and caveats
None reported.

Participant flow

Study started on 23-Sep-2008 and enrolled 224 subjects from Canada.

Participant flow — Overall Study
MilestoneInfanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal Group
Started112112
Completed105112
Not completed70
Withdrew: Migrated/moved from study area10
Withdrew: Lost to follow-up-incomplete vaccination30
Withdrew: Lost to follow-up-complete vaccination10
Withdrew: Protocol violation20

Outcome measures

PrimaryNumber of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (Anti-PRP)

A seroprotected subject was a subject whose anti-PRP antibody concentration was greater or equal to (≥) 0.15 microgram per milliliter (µg/mL).

Time frame:
One month after (POST) Dose 3.
Reported as:
Number · Subjects
Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (Anti-PRP)
SubjectsInfanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal Group
Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (Anti-PRP)92106
SecondaryNumber of Subjects With Anti-PRP Antibody Concentrations ≥1µg/mL

For this assay, 1 μg/mL was considered as the seropositivity cut-off.

Time frame:
One month after (POST) Dose 3.
Reported as:
Number · Subjects
Number of Subjects With Anti-PRP Antibody Concentrations ≥1µg/mL
SubjectsInfanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal Group
Number of Subjects With Anti-PRP Antibody Concentrations ≥1µg/mL8391
SecondaryAnti-PRP Antibody Concentrations

Anti-PRP antibody concentrations were presented as Geometric mean Concentrations (GMC), expressed as micrograms per milliliter (μg/mL).

Time frame:
One month after (POST) Dose 3.
Reported as:
Geometric mean · µg/mL
Anti-PRP Antibody Concentrations
µg/mLInfanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal Group
Anti-PRP Antibody Concentrations6.123 (4.498 to 8.334)3.51 (2.745 to 4.488)
SecondaryNumber of Seroprotected Subjects Against Hepatitis B (Anti-HBs)

A seroprotected subject was a subject with anti-HBs antibody concentrations ≥ 10 milli-International Units ler milliliter (mIU/mL). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following partial or complete retesting/reanalysis. Some of the available blood samples initially tested with ELISA were re-tested using the new assay, CLIA.

Time frame:
One month after (POST) Dose 3.
Reported as:
Number · Subjects
Number of Seroprotected Subjects Against Hepatitis B (Anti-HBs)
SubjectsInfanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal Group
Number of Seroprotected Subjects Against Hepatitis B (Anti-HBs)91103
SecondaryNumber of Subjects With Anti-HBs Antibody Concentrations ≥100 mIU/mL

The testing was done using the Enzyme-Linked Immunosorbent assay (ELISA) assay.

Time frame:
One month after (POST) Dose 3.
Reported as:
Number · Subjects
Number of Subjects With Anti-HBs Antibody Concentrations ≥100 mIU/mL
SubjectsInfanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal Group
Number of Subjects With Anti-HBs Antibody Concentrations ≥100 mIU/mL89100
SecondaryAnti-HBs Antibody Concentrations

Anti-HBs antibody concentrations were assessed by Enzyme-Linked Immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs).

Time frame:
One month after (POST) Dose 3.
Reported as:
Geometric mean · mIU/mL
Anti-HBs Antibody Concentrations
mIU/mLInfanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal Group
Anti-HBs Antibody Concentrations1797.9 (1375.1 to 2350.7)1544.4 (1210.4 to 1970.5)
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

Time frame:
During the 31 day (Days 0-30) post vaccination
Reported as:
Number · Subjects
Number of Subjects With Unsolicited Adverse Events (AEs)
SubjectsInfanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal Group
Number of Subjects With Unsolicited Adverse Events (AEs)2619
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
During the entire study period up to Last subject last visit on 03/12/2013
Reported as:
Number · Subjects
Number of Subjects With Serious Adverse Events (SAEs)
SubjectsInfanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal Group
Number of Subjects With Serious Adverse Events (SAEs)60

Adverse events

Collected over Unsolicited AEs during the 31-day post-vaccination period, SAEs during the entire period up to Last subject last visit on 03/12/2013.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infanrix Hexa Aboriginal Group—6/112 (5.4%)6/112 (5.4%)
Infanrix Hexa Non-Aboriginal Group—0/112 (0%)0/112 (0%)
Most frequent serious events
Most frequent serious events
EventInfanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal Group
ConvulsionNervous system disorders2/1120/112
Febrile convulsionNervous system disorders1/1120/112
PyrexiaGeneral disorders1/1120/112
BronchiolitisInfections and infestations1/1120/112
Pneumonia bacterialInfections and infestations1/1120/112
Respiratory syncytial virus infectionInfections and infestations1/1120/112
Most frequent other events
Most frequent other events
EventInfanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal Group
PyrexiaGeneral disorders6/1120/112

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)Infanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal GroupTotal
Mean9.3 ± 1.389.2 ± 1.39.25 ± 1.34
Sex: Female, Male
Sex: Female, Male(Participants)Infanrix Hexa Aboriginal GroupInfanrix Hexa Non-Aboriginal GroupTotal
Female6252114
Male5060110
08

Study locations

3 sites
  • GSK Investigational Site
    Edmonton, Alberta T5M 3Z7, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 4H4, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
09

References and documents

Publications

  • Scheifele DW, Ferguson M, Predy G, Dawar M, Assudani D, Kuriyakose S, Van Der Meeren O, Han HH. Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants. Vaccine. 2015 Apr 15;33(16):1897-900. doi: 10.1016/j.vaccine.2015.02.015. Epub 2015 Feb 18. PubMed 25701314 ↗

Individual participant data

Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2008 to primary completion in Mar 2013, 53 months.

Results were first posted in Nov 2016, 3 years 8 months after primary completion. A results delay was requested in Apr 2013.

Of 63 phase 4 interventional studies under Hepatitis B, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's 53 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2008
First posted
Sep 16, 2008
StartActual
Sep 23, 2008
Primary completionActual
Mar 12, 2013
CompletionActual
Mar 12, 2013
Results delay requested
Apr 11, 2013
Results first posted
Nov 30, 2016
Last update
Nov 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00753649
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 16, 2008
Start date
Sep 23, 2008
Primary completion
Mar 12, 2013
Completion
Mar 12, 2013
Results posted
Nov 30, 2016
Last update
Nov 27, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion